China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.49
(-0.8%)
USD 2.49
(-0.8%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 117.12 Thousand USD | -0.62% |
| 2023 | 365.82 Thousand USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 6292.00 USD | -82.77% |
| 2020 | 36.51 Thousand USD | -12.46% |
| 2019 | 41.71 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q4 | 294.66 Thousand USD | 0.0% |
| 2024 Q2 | 106.57 Thousand USD | 0.0% |
| 2024 FY | 117.12 Thousand USD | -67.98% |
| 2024 Q3 | 117.12 Thousand USD | 9.9% |
| 2024 Q1 | 311.51 Thousand USD | -9.58% |
| 2023 FY | 365.82 Thousand USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q3 | 365.82 Thousand USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q4 | 365.82 Thousand USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q1 | - USD | -100.0% |
| 2021 Q2 | 15.21 Thousand USD | 0.0% |
| 2021 FY | 6292.00 USD | -82.77% |
| 2021 Q3 | 6292.00 USD | -58.64% |
| 2021 Q1 | 15.21 Thousand USD | -58.33% |
| 2021 Q4 | 6292.00 USD | 0.0% |
| 2020 FY | 36.51 Thousand USD | -12.46% |
| 2020 Q2 | 873.28 Thousand USD | 0.0% |
| 2020 Q4 | 36.51 Thousand USD | 0.0% |
| 2020 Q3 | 36.51 Thousand USD | -95.82% |
| 2020 Q1 | 873.28 Thousand USD | 1993.7% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 41.71 Thousand USD | 0.01% |
| 2019 Q3 | 41.7 Thousand USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 FY | 41.71 Thousand USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Journey Medical Corporation | 14.62 Million USD | 99.199% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 99.962% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 99.871% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 99.977% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 78.271% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | 78.271% |
| SCYNEXIS, Inc. | 12.15 Million USD | 99.037% |
| Safety Shot Inc | 304.9 Thousand USD | 61.585% |
| Alpha Teknova, Inc. | 13.25 Million USD | 99.116% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 99.976% |
| Bright Green Corporation | 201.78 Thousand USD | 41.953% |
| Dynavax Technologies Corporation | 252.41 Million USD | 99.954% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 99.977% |
| Cosmos Health Inc. | 3.03 Million USD | 96.141% |
| PainReform Ltd. | 30 Thousand USD | -290.43% |
| Embecta Corp. | 1.62 Billion USD | 99.993% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | 99.121% |
| Procaps Group, S.A. | 28.41 Million USD | 99.588% |
| Theratechnologies Inc. | 51.26 Million USD | 99.772% |
| Harrow Health, Inc. | 183.17 Million USD | 99.936% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -34.631% |
| Biofrontera Inc. | 804 Thousand USD | 85.432% |
| DURECT Corporation | 2.7 Million USD | 95.665% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 99.647% |
| Cronos Group Inc. | 1.55 Million USD | 92.487% |
| OptiNose, Inc. | 611 Thousand USD | 80.83% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 99.976% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 99.657% |
| RedHill Biopharma Ltd. | 455 Thousand USD | 74.257% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 99.807% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | 99.084% |
| Radius Health, Inc. | 339.66 Million USD | 99.966% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | 98.858% |
| Phibro Animal Health Corporation | 458.28 Million USD | 99.974% |
| Procaps Group S.A. | 28.41 Million USD | 99.588% |
| Alvotech | 1.02 Billion USD | 99.989% |
| TherapeuticsMD, Inc. | 6.53 Million USD | 98.207% |
| Viatris Inc. | 16.18 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 8.29 Million USD | 98.588% |
| Aytu BioPharma, Inc. | 10.87 Million USD | 98.923% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | 65.139% |
| Tilray Brands, Inc. | 287.93 Million USD | 99.959% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 99.903% |
| Shineco, Inc. | 10.01 Million USD | 98.831% |
| PetIQ, Inc. | 437.82 Million USD | 99.973% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | 44.224% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 99.955% |
| Alimera Sciences, Inc. | 64.48 Million USD | 99.818% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 99.696% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | 13.295% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | 98.292% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | 83.732% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -420.944% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | 99.642% |
| Hempacco Co., Inc. | 5.93 Million USD | 98.025% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 99.989% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 99.792% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 99.981% |
| Currenc Group, Inc. | 2.5 Million USD | 95.328% |
| Kamada Ltd. | 7.43 Million USD | 98.425% |
| Indivior PLC | 235.66 Million USD | 99.95% |
| Evoke Pharma, Inc. | 5 Million USD | 97.657% |
| Flora Growth Corp. | 942 Thousand USD | 87.566% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -420.944% |
| Evolus, Inc. | 120.35 Million USD | 99.903% |
| HUTCHMED (China) Limited | 48.18 Million USD | 99.757% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 99.98% |
| Akanda Corp. | 2.49 Million USD | 95.31% |